File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC

TitleRecent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
Authors
Keywordshepatocellular carcinoma
biomarker
checkpoint inhibitors
combination therapy
targeted therapy
Issue Date2021
PublisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/
Citation
Cancers, 2021, v. 13 n. 8, p. article no. 1949 How to Cite?
AbstractAdvanced, unresectable hepatocellular carcinoma has a dismal outcome. Multiple immune checkpoint inhibitors (ICIs) targeting the programmed-cell death 1 pathway (PD-1/L1) have been approved for the treatment of advanced HCC. However, outcomes remain undesirable and unpredictable on a patient-to-patient basis. The combination of anti-PD-1/L1 with alternative agents, chiefly cytotoxic T-lymphocyte antigen-4 (CTLA-4) ICIs or agents targeting other oncogenic pathways such as the vascular endothelial growth factor (VEGF) pathway and the c-MET pathway, has, in addition to the benefit of directly targeting alterative oncogenic pathways, in vitro evidence of synergism through altering the genomic and function signatures of T cells and expression of immune checkpoints. Several trials have been completed or are underway evaluating such combinations. Finally, studies utilizing transcriptomics and organoids are underway to establish biomarkers to predict ICI response. This review aims to discuss the biological rationale and clinical advances in ICI-based combinations in HCCs, as well as the progress and prospects of the search for the aforementioned biomarkers in ICI treatment of HCC.
Persistent Identifierhttp://hdl.handle.net/10722/301934
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.391
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDong, Y-
dc.contributor.authorWong, JSL-
dc.contributor.authorSugimura, R-
dc.contributor.authorLam, KO-
dc.contributor.authorLi, B-
dc.contributor.authorKwok, GGW-
dc.contributor.authorLeung, R-
dc.contributor.authorChiu, JWY-
dc.contributor.authorCheung, TT-
dc.contributor.authorYan, T-
dc.date.accessioned2021-08-21T03:29:08Z-
dc.date.available2021-08-21T03:29:08Z-
dc.date.issued2021-
dc.identifier.citationCancers, 2021, v. 13 n. 8, p. article no. 1949-
dc.identifier.issn2072-6694-
dc.identifier.urihttp://hdl.handle.net/10722/301934-
dc.description.abstractAdvanced, unresectable hepatocellular carcinoma has a dismal outcome. Multiple immune checkpoint inhibitors (ICIs) targeting the programmed-cell death 1 pathway (PD-1/L1) have been approved for the treatment of advanced HCC. However, outcomes remain undesirable and unpredictable on a patient-to-patient basis. The combination of anti-PD-1/L1 with alternative agents, chiefly cytotoxic T-lymphocyte antigen-4 (CTLA-4) ICIs or agents targeting other oncogenic pathways such as the vascular endothelial growth factor (VEGF) pathway and the c-MET pathway, has, in addition to the benefit of directly targeting alterative oncogenic pathways, in vitro evidence of synergism through altering the genomic and function signatures of T cells and expression of immune checkpoints. Several trials have been completed or are underway evaluating such combinations. Finally, studies utilizing transcriptomics and organoids are underway to establish biomarkers to predict ICI response. This review aims to discuss the biological rationale and clinical advances in ICI-based combinations in HCCs, as well as the progress and prospects of the search for the aforementioned biomarkers in ICI treatment of HCC.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/-
dc.relation.ispartofCancers-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjecthepatocellular carcinoma-
dc.subjectbiomarker-
dc.subjectcheckpoint inhibitors-
dc.subjectcombination therapy-
dc.subjecttargeted therapy-
dc.titleRecent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC-
dc.typeArticle-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.authorityLam, KO=rp01501-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/cancers13081949-
dc.identifier.pmid33919570-
dc.identifier.pmcidPMC8072916-
dc.identifier.scopuseid_2-s2.0-85104312427-
dc.identifier.hkuros324222-
dc.identifier.hkuros326130-
dc.identifier.volume13-
dc.identifier.issue8-
dc.identifier.spagearticle no. 1949-
dc.identifier.epagearticle no. 1949-
dc.identifier.isiWOS:000643976200001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats